DOCSLIB.ORG

Type 1 Established Condition List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Type 1 Established Condition List Part C of the IDEA and Family Education and Support Programs: Use of the Established Condition List for Type I Eligibility May 23, 2019 When determining Type I Eligibility for Part C of the IDEA and Family Education and Support Programs: 1. The Program providers use the Established Condition Statement as completed and signed by a physician or psychologist. 2. After receipt of the Statement, the Program providers' designated personnel will refer to this Established Condition List to determine if the child's condition is one that is identified as meeting Type I Established Condition criteria in the Montana. 3. If yes, the Program provider completes the multidisciplinary assessment (with written consent from the family) of the child's needs and family's concerns, priorities, and resources to enhance the development of the child for the development of the IFSP. 4. If no, the Program provider (with written consent from the family) moves toward establishing Type II Measured Delay eligibility (50% delay in one developmental domain or two or more 25% delays in developmental domains) using a multidisciplinary evaluation team that includes the family, the service coordinator, and at least one other discipline. 5. If yes, the child meets Type II Measured Delay eligibility, the Program provider completes (with written consent from the family) the multidisciplinary assessment of the child's needs and family's concerns, priorities, and resources to enhance the development of the child for the development of the IFSP. 6. If no, the family receives written notification of the eligibility decision and the Program provider shares more appropriate referrals with the family. 7. Eligibility is determined annually, and child assessments are completed at least annually to monitor development and appropriately develop IFSPs based upon the child's assessed developmental needs and the family's concerns, priorities, and resources to enhance the development of the child. 1 | Page Montana DPHHS Part C of the IDEA Program and FES Program Established Condition List 6 12 2019 The following conditions meet the Type I Established Condition criteria in Montana The following conditions meet the Type I Established Condition criteria for Montana DPHHS Part C of the IDEA Program and FES Program 6 12 19. Medical Diagnosis Name Diagnosis Details Acrocallosal Syndrome, Schinzel Acrocallosal Syndrome, Schinzel Type (aka: Schinzel Acrocallosal Syndrome; Acrocallosal Syndrome, Schinzel Type; ACLS; ACS; Hallux duplication, postaxial polydactyly, absence of the corpus callosum, severe mental retardation syndrome) Adrenoleukodystrophy Adrenoleukodystrophy (aka: ALD; AMN; X-ALD; Addison disease and cerebral sclerosis; Adrenomyeloneuropathy; Siemerling-creutzfeldt disease; Bronze schilder disease; Schilder Disease; Melanodermic Leukodystrophy; sudanophilic leukodystrophy; Pelizaeus Merz... Agenesis of Corpus Callosum Agenesis of the Corpus Callosum (aka: Absence of the corpus callosum; Hypogenesis of the corpus callosum; Dysplastic corpus callosum) Aicardi Syndrome Aicardi Syndrome (aka: Agenesis of Corpus Callosum and Chorioretinal Abnormality; Agenesis of Corpus Callosum With Chorioretinitis Abnormality; Agenesis of Corpus Callosum With Infantile Spasms and Ocular Anomalies; Chorioretinal Anomalies with Agenesis ... Alexander Disease Alexander Disease Allan Herndon Syndrome Allan Herndon Syndrome (aka: Allan-Herndon-Dudley Syndrome (AHDS); Allan-Herndon-Dudley Mental Retardation) Alper Disease Alper Disease (aka: Alper's Diffuse Degeneration of Cerebral Gray Matter with Hepatic Cirrhosis; Alpers Progressive Infantile Poliodystrophy; Christensen's disease; Christensen-Krabbe disease; Diffuse Cerebral Degeneration in Infancy; Poliodystrophia Cer... Anencephaly Anencephaly Angelman Syndrome Angelman Syndrome (aka: AS) Aniridia Cerebellar Ataxia MD Aniridia Cerebellar Ataxia Mental Deficiency (aka: Gillespie syndrome; Aniridia, Partial-Cerebellar Ataxia-Oligophrenia; Aniridia-Cerebellar Ataxia-Mental Retardation)hrenia) Anophthalmia, bilateral Anophthalmia, bilateral Aphasia w brain damage Aphasia (with evidence of brain damage) (aka: aphemia with evidence of brain damage) Argininosuccinic aciduria Argininosuccinic aciduria (aka: Arginino Succinase Deficiency; ASA Deficiency; Argininosuccinate Lyase Deficiency; ASL Deficiency) 2 | Page The following conditions meet the Type I Established Condition criteria for Montana DPHHS Part C of the IDEA Program and FES Program 6 12 19. Medical Diagnosis Name Diagnosis Details Asphyxia w brain damage Asphyxia (with evidence of brain damage within athe first couple days of the event) Autism Spectrum Disorder Autism Spectrum Disorder (aka: Infantile Autism; Kanner Syndrome; Autistic Disorder; Asperger Syndrome; Asperger's Disorder; Pervasive Developmental Disorder; PDD; Pervasive Developmental Disorder-Not Otherwise Specified; PDD-NOS) Baller Gerold Syndrome Baller Gerold Syndrome (aka: Craniosynostosis with Radial Defects, Craniosynostosis-Radial Aplasia Syndrome) Bannayan Riley Ruvalcaba Bannayan Riley Ruvalcaba (aka: Bannayan Riley Ruvalcaba Syndrome; BRRS, Bannayan-Zonana syndrome (BZS); Macrocephaly, multiple lipomas, and hemangiomata; Macrocephaly, pseudopapilledema, and multiple hemangiomata; Riley-Smith syndrome; Ruvalcaba-Myhre-Sm... Bardet-Biedl Syndrome Bardet-Biedl Syndrome (aka: Biedl-Bardet Syndrome; Laurence Moon-Biedl) Batten Disease Batten Disease (aka: CLN3, JNCL, Neuronal Ceroid Lipofuscinosis, Juvenile, Spielmeyer-Sjogren Disease, Vogt-Spielmeyer Disease, or Vogt-Spielmeyer-Sjogren Disease) Borjeson Syndrome Borjeson Syndrome (aka: BORJ; Borjeson-Forssman-Lehmann Syndrome; BFLS) Brain Tumor Brain Tumor (aka: brain cancer; brain teratoma; glioma; astrocytoma; glioblastoma multiforme; ependymoma; oligodendroglioma; medulloblastoma; meningioma; Schwannoma; acoustic neuroma; craniopharyngioma; germ cell tumor of the brain; germinoma; pineal reg... C Syndrome C Syndrome (aka: Opitz Trigonocephaly Syndrome, Trigonocephaly "C" Syndrome, Trigonocephaly Syndrome) Cardiofaciocutaneous Syndrome Cardiofaciocutaneous syndrome (aka: CFC syndrome, Cardio-facial-cutaneous syndrome, Facio-cardio- cutaneous syndrome) Cerebellar agenesis Cerebellar Agenesis (aka: Cerebellar Aplasia; Cerebellar Hemiagenesis; Cerebellar Hypoplasia; Cerebellar Atrophy) Cerebral atrophy Cerebral atrophy Cerebral Dysgenesis Cerebral Dysgenesiias Cerebro Oculo Facio Skel Syndrome Cerebro Oculo Facio Skeletal Syndrome (aka: COFS Syndrome, Cerebrooculofacioskeletal Syndrome, Cockayne Syndrome type II, Pena Shokeir II Syndrome, Pena Shokeir Syndrome Type II) Cerebromalacia Cerebromalacia (aka: Encephalomalacia) CHAMP 1 Champ 1 gene mutation CHARGE Syndrome CHARGE Syndrome (aka: CHARGE Association) 3 | Page The following conditions meet the Type I Established Condition criteria for Montana DPHHS Part C of the IDEA Program and FES Program 6 12 19. Medical Diagnosis Name Diagnosis Details Chromosome 10, Monosomy 10p Chromosome 10, Monosomy 10p (aka: 10p Deletion Syndrome (Partial); Chromosome 10, 10p- Partial; Chromosome 10, Partial Deletion (short arm)) Chromosome 11, Partial Monosomy 11q Chromosome 11, Partial Monosomy 11q (aka: 11q- Syndrome; Partial, Deletion 11q Syndrome, Partial; Distal 11q Monosomy; Distal 11q- Syndrome; JBS; Jacobsen Syndrome; Monosomy 11q, Partial; Partial Monosomy of Long Arm of Chromosome 11; 11q14 deletion; 11q21 deletion; 11q14-21 deletion) Chromosome 11, Partial Trisomy 11p14.3 Chromosome 11, Partial Trisomy 11p14.3 Chromosome 11, Partial Trisomy 11q Chromosome 11, Partial Trisomy 11q (aka: 11q Partial Trisomy, Chromosome 11; Partial Trisomy 11q13-qter, Chromosome 11; Partial Trisomy 11q21-qter;, Chromosome 11; Partial Trisomy 11q23- qter; Distal Trisomy 11q; Partial Trisomy 11q; Trisomy 11q, Partial) Chromosome 12 Deletion Chromosome 12 deletion Chromosome 12 Partial Trisomy Partial Trisomy 12 Chromosome 13, Partial Monosomy 13q Chromosome 13, Partial Monosomy 13q (aka: 13q- Syndrome, Partial; Deletion 13q Syndrome, Partial; Monosomy 13q, Partial; Partial Monosomy of the Long Arm of Chromosome 13) Chromosome 14 Deletion Chromosome 14 deletion Chromosome 14 Ring Chromosome 14 Ring (aka: Ring 14; Ring Chromosome 14; r14) Chromosome 14, Trisomy Mosaic Chromosome 14, Trisomy Mosaic (aka: Trisomy 14 Mosaic; Trisomy 14 Mosaicism Syndrome; Trisomy 14 Syndrome) Chromosome 15 Ring Chromosome 15 Ring (aka: Ring 15; Ring 15 Chromosome; Ring 15 Chromosome (mosaic pattern); r15) Chromosome 15, Distal Trisomy 15q Chromosome 15, Distal Trisomy 15q (aka: Chromosome 15, Trisomy 15q2; Distal Duplication 15q; Partial Duplication 15q Syndrome) Chromosome 15q11-q13 Dup Chromosome 15q11-q13 duplication (aka: Isodicentric 15; Inverted duplication 15) Chromosome 15q24 microdeletion Chromosome 15q24 Microdeletion Syndrome syndrome Chromosome 16 Duplication Chromosome 16 Duplication Chromosome 17q12 Duplication Chromosome 17q12 Duplication Chromosome 18 Ring Chromosome 18 Ring (aka: Ring 18; Ring Chromosome 18; r18) Chromosome 18, Tetrasomy 18p Chromosome 18, Tetrasomy 18p (aka: Tetrasomy, Short Arm of Chromosome 18) Chromosome 19p duplication Chromosome 19p duplication 4 | Page The following conditions meet the Type I Established Condition criteria for Montana DPHHS Part C of the IDEA Program and FES Program 6 12 19. Medical Diagnosis Name Diagnosis Details Chromosome 20q Trisomy Chromosome 20q Trisomy (aka: Chromosome 20q Duplication; Partial Trisomy 20q; Trisomy 20q11.2; Chromosome 20q11.2 Duplication; Trisomy 20) Chromosome 22 Ring Chromosome 22 Ring
Load more

Recommended publications
  • Inherited Cerebellar Ataxia in Childhood: a Pattern-Recognition Approach Using Brain MRI
    REVIEW ARTICLE Inherited Cerebellar Ataxia in Childhood: A Pattern-Recognition Approach Using Brain MRI L. Vedolin, G. Gonzalez, C.F. Souza, C. Lourenc¸o, and A.J. Barkovich ABSTRACT SUMMARY: Ataxia is the principal symptom of many common neurologic diseases in childhood. Ataxias caused by dysfunction of the cerebellum occur in acute, intermittent, and progressive disorders. Most of the chronic progressive processes are secondary to degen- erative and metabolic diseases. In addition, congenital malformation of the midbrain and hindbrain can also be present, with posterior fossa symptoms related to ataxia. Brain MR imaging is the most accurate imaging technique to investigate these patients, and imaging abnormalities include size, shape, and/or signal of the brain stem and/or cerebellum. Supratentorial and cord lesions are also common. This review will discuss a pattern-recognition approach to inherited cerebellar ataxia in childhood. The purpose is to provide a comprehensive discussion that ultimately could help neuroradiologists better manage this important topic in pediatric neurology. ABBREVIATIONS: AR ϭ autosomal recessive; CAC ϭ cerebellar ataxia in childhood; 4H ϭ hypomyelination with hypogonadotropic hypogonadism and hypodon- tia; JSRD ϭ Joubert syndrome and related disorders; OPHN1 ϭ oligophrenin-1 taxia is an inability to coordinate voluntary muscle move- plastic/paraneoplastic disorders, immune-mediated/demyelinat- Aments that cannot be attributed to weakness or involuntary ing disorders, and drugs/toxins (antiepileptic medications,
    [Show full text]
  • The National Economic Burden of Rare Disease Study February 2021
    Acknowledgements This study was sponsored by the EveryLife Foundation for Rare Diseases and made possible through the collaborative efforts of the national rare disease community and key stakeholders. The EveryLife Foundation thanks all those who shared their expertise and insights to provide invaluable input to the study including: the Lewin Group, the EveryLife Community Congress membership, the Technical Advisory Group for this study, leadership from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), the Undiagnosed Diseases Network (UDN), the Little Hercules Foundation, the Rare Disease Legislative Advocates (RDLA) Advisory Committee, SmithSolve, and our study funders. Most especially, we thank the members of our rare disease patient and caregiver community who participated in this effort and have helped to transform their lived experience into quantifiable data. LEWIN GROUP PROJECT STAFF Grace Yang, MPA, MA, Vice President Inna Cintina, PhD, Senior Consultant Matt Zhou, BS, Research Consultant Daniel Emont, MPH, Research Consultant Janice Lin, BS, Consultant Samuel Kallman, BA, BS, Research Consultant EVERYLIFE FOUNDATION PROJECT STAFF Annie Kennedy, BS, Chief of Policy and Advocacy Julia Jenkins, BA, Executive Director Jamie Sullivan, MPH, Director of Policy TECHNICAL ADVISORY GROUP Annie Kennedy, BS, Chief of Policy & Advocacy, EveryLife Foundation for Rare Diseases Anne Pariser, MD, Director, Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health Elisabeth M. Oehrlein, PhD, MS, Senior Director, Research and Programs, National Health Council Christina Hartman, Senior Director of Advocacy, The Assistance Fund Kathleen Stratton, National Academies of Science, Engineering and Medicine (NASEM) Steve Silvestri, Director, Government Affairs, Neurocrine Biosciences Inc.
    [Show full text]
  • Neonatal Dermatology Review
    NEONATAL Advanced Desert DERMATOLOGY Dermatology Jennifer Peterson Kevin Svancara Jonathan Bellew DISCLOSURES No relevant financial relationships to disclose Off-label use of acitretin in ichthyoses will be discussed PHYSIOLOGIC Vernix caseosa . Creamy biofilm . Present at birth . Opsonizing, antibacterial, antifungal, antiparasitic activity Cutis marmorata . Reticular, blanchable vascular mottling on extremities > trunk/face . Response to cold . Disappears on re-warming . Associations (if persistent) . Down syndrome . Trisomy 18 . Cornelia de Lange syndrome PHYSIOLOGIC Milia . Hard palate – Bohn’s nodules . Oral mucosa – Epstein pearls . Associations . Bazex-Dupre-Christol syndrome (XLD) . BCCs, follicular atrophoderma, hypohidrosis, hypotrichosis . Rombo syndrome . BCCs, vermiculate atrophoderma, trichoepitheliomas . Oro-facial-digital syndrome (type 1, XLD) . Basal cell nevus (Gorlin) syndrome . Brooke-Spiegler syndrome . Pachyonychia congenita type II (Jackson-Lawler) . Atrichia with papular lesions . Down syndrome . Secondary . Porphyria cutanea tarda . Epidermolysis bullosa TRANSIENT, NON-INFECTIOUS Transient neonatal pustular melanosis . Birth . Pustules hyperpigmented macules with collarette of scale . Resolve within 4 weeks . Neutrophils Erythema toxicum neonatorum . Full term . 24-48 hours . Erythematous macules, papules, pustules, wheals . Eosinophils Neonatal acne (neonatal cephalic pustulosis) . First 30 days . Malassezia globosa & sympoidalis overgrowth TRANSIENT, NON-INFECTIOUS Miliaria . First weeks . Eccrine
    [Show full text]
  • A Brazilian Cohort of Individuals with Phelan-Mcdermid Syndrome
    Samogy-Costa et al. Journal of Neurodevelopmental Disorders (2019) 11:13 https://doi.org/10.1186/s11689-019-9273-1 RESEARCH Open Access A Brazilian cohort of individuals with Phelan-McDermid syndrome: genotype- phenotype correlation and identification of an atypical case Claudia Ismania Samogy-Costa1†, Elisa Varella-Branco1†, Frederico Monfardini1, Helen Ferraz2, Rodrigo Ambrósio Fock3, Ricardo Henrique Almeida Barbosa3, André Luiz Santos Pessoa4,5, Ana Beatriz Alvarez Perez3, Naila Lourenço1, Maria Vibranovski1, Ana Krepischi1, Carla Rosenberg1 and Maria Rita Passos-Bueno1* Abstract Background: Phelan-McDermid syndrome (PMS) is a rare genetic disorder characterized by global developmental delay, intellectual disability (ID), autism spectrum disorder (ASD), and mild dysmorphisms associated with several comorbidities caused by SHANK3 loss-of-function mutations. Although SHANK3 haploinsufficiency has been associated with the major neurological symptoms of PMS, it cannot explain the clinical variability seen among individuals. Our goals were to characterize a Brazilian cohort of PMS individuals, explore the genotype-phenotype correlation underlying this syndrome, and describe an atypical individual with mild phenotype. Methodology: A total of 34 PMS individuals were clinically and genetically evaluated. Data were obtained by a questionnaire answered by parents, and dysmorphic features were assessed via photographic evaluation. We analyzed 22q13.3 deletions and other potentially pathogenic copy number variants (CNVs) and also performed genotype-phenotype correlation analysis to determine whether comorbidities, speech status, and ASD correlate to deletion size. Finally, a Brazilian cohort of 829 ASD individuals and another independent cohort of 2297 ID individuals was used to determine the frequency of PMS in these disorders. Results: Our data showed that 21% (6/29) of the PMS individuals presented an additional rare CNV, which may contribute to clinical variability in PMS.
    [Show full text]
  • Journal of Medical Genetics April 1992 Vol 29 No4 Contents Original Articles
    Journal of Medical Genetics April 1992 Vol 29 No4 Contents Original articles Beckwith-Wiedemann syndrome: a demonstration of the mechanisms responsible for the excess J Med Genet: first published as on 1 April 1992. Downloaded from of transmitting females C Moutou, C Junien, / Henry, C Bonai-Pellig 217 Evidence for paternal imprinting in familial Beckwith-Wiedemann syndrome D Viljoen, R Ramesar 221 Sex reversal in a child with a 46,X,Yp+ karyotype: support for the existence of a gene(s), located in distal Xp, involved in testis formation T Ogata, J R Hawkins, A Taylor, N Matsuo, J-1 Hata, P N Goodfellow 226 Highly polymorphic Xbol RFLPs of the human 21 -hydroxylase genes among Chinese L Chen, X Pan, Y Shen, Z Chen, Y Zhang, R Chen 231 Screening of microdeletions of chromosome 20 in patients with Alagille syndrome C Desmaze, J F Deleuze, A M Dutrillaux, G Thomas, M Hadchouel, A Aurias 233 Confirmation of genetic linkage between atopic IgE responses and chromosome 1 1 ql 3 R P Young, P A Sharp, J R Lynch, J A Faux, G M Lathrop, W 0 C M Cookson, J M Hopkini 236 Age at onset and life table risks in genetic counselling for Huntington's disease P S Harper, R G Newcombe 239 Genetic and clinical studies in autosomal dominant polycystic kidney disease type 1 (ADPKD1) E Coto, S Aguado, J Alvarez, M J Menendez-DIas, C Lopez-Larrea 243 Short communication Evidence for linkage disequilibrium between D16S94 and the adult onset polycystic kidney disease (PKD1) gene S E Pound, A D Carothers, P M Pignatelli, A M Macnicol, M L Watson, A F Wright 247 Technical note A strategy for the rapid isolation of new PCR based DNA polymorphisms P R Hoban, M F Santibanez-Koref, J Heighway 249 http://jmg.bmj.com/ Case reports Campomelic dysplasia associated with a de novo 2q;1 7q reciprocal translocation I D Young, J M Zuccollo, E L Maltby, N J Broderick 251 A complex chromosome rearrangement with 10 breakpoints: tentative assignment of the locus for Williams syndrome to 4q33-q35.1 R Tupler, P Maraschio, A Gerardo, R Mainieri G Lanzi L Tiepolo 253 on September 26, 2021 by guest.
    [Show full text]
  • A Randomized Controlled Trial of Intranasal Oxytocin in Phelan-Mcdermid Syndrome
    A Randomized Controlled Trial of Intranasal Oxytocin in Phelan-McDermid Syndrome Jarrett Fastman Icahn School of Medicine at Mount Sinai Jennifer Foss-Feig Icahn School of Medicine at Mount Sinai Yitzchak Frank Icahn School of Medicine at Mount Sinai Danielle Halpern Icahn School of Medicine at Mount Sinai Hala Harony-Nicolas Icahn School of Medicine at Mount Sinai Christina Layton Icahn School of Medicine at Mount Sinai Sven Sandin Icahn School of Medicine at Mount Sinai Paige Siper Icahn School of Medicine at Mount Sinai Lara Tang Icahn School of Medicine at Mount Sinai Pilar Trelles Icahn School of Medicine at Mount Sinai Jessica Zweifach Icahn School of Medicine at Mount Sinai Joseph D. Buxbaum Icahn School of Medicine at Mount Sinai Alexander Kolevzon ( [email protected] ) Icahn School of Medicine at Mount Sinai https://orcid.org/0000-0001-8129-2671 Research Article Keywords: Phelan-McDermid syndrome, PMS, shank3, autism spectrum disorder, ASD, oxytocin Posted Date: March 5th, 2021 Page 1/24 DOI: https://doi.org/10.21203/rs.3.rs-268151/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 2/24 Abstract Background Phelan-McDermid syndrome (PMS) is a rare neurodevelopmental disorder caused by haploinsuciency of the SHANK3 gene and characterized by global developmental delays, decits in speech and motor function, and autism spectrum disorder (ASD). Monogenic causes of ASD such as PMS are well suited to investigations with novel therapeutics, as interventions can be targeted based on established genetic etiology. While preclinical studies have demonstrated that the neuropeptide oxytocin can reverse electrophysiological, attentional, and social recognition memory decits in Shank3-decient rats, there have been no trials in individuals with PMS.
    [Show full text]
  • 22Q13.3 Deletion Syndrome
    22q13.3 deletion syndrome Description 22q13.3 deletion syndrome, which is also known as Phelan-McDermid syndrome, is a disorder caused by the loss of a small piece of chromosome 22. The deletion occurs near the end of the chromosome at a location designated q13.3. The features of 22q13.3 deletion syndrome vary widely and involve many parts of the body. Characteristic signs and symptoms include developmental delay, moderate to profound intellectual disability, decreased muscle tone (hypotonia), and absent or delayed speech. Some people with this condition have autism or autistic-like behavior that affects communication and social interaction, such as poor eye contact, sensitivity to touch, and aggressive behaviors. They may also chew on non-food items such as clothing. Less frequently, people with this condition have seizures or lose skills they had already acquired (developmental regression). Individuals with 22q13.3 deletion syndrome tend to have a decreased sensitivity to pain. Many also have a reduced ability to sweat, which can lead to a greater risk of overheating and dehydration. Some people with this condition have episodes of frequent vomiting and nausea (cyclic vomiting) and backflow of stomach acids into the esophagus (gastroesophageal reflux). People with 22q13.3 deletion syndrome typically have distinctive facial features, including a long, narrow head; prominent ears; a pointed chin; droopy eyelids (ptosis); and deep-set eyes. Other physical features seen with this condition include large and fleshy hands and/or feet, a fusion of the second and third toes (syndactyly), and small or abnormal toenails. Some affected individuals have rapid (accelerated) growth.
    [Show full text]
  • Practitioners' Section
    407 408 GENETICS OF MENTAL RETARDATION [2] [4] PRACTITIONERS’ SECTION epiphenomena. A specific cause for mental a group heritability of 0.49. The aetiology of retardation can be identified in approximately idiopathic mental retardation is usually 80% of people with SMR (IQ<50) and 50% of explained in terms of the ‘polygenic GENETICS OF MENTAL RETARDATION people with MMR (IQ 50–70). multifactorial model.’ The difficulty is that there A. S. AHUJA, ANITA THAPAR, M. J. OWEN are too few studies to provide sufficiently In this article, we will begin by considering precise estimates of the likely role of genes ABSTRACT what is known about the genetics of idiopathic and environment in determining idiopathic mental retardation and then move onto discuss mental retardation. Given the dearth of Mental retardation can follow any of the biological, environmental and psychological events that are capable of producing deficits in cognitive functions. specific genetic causes of mental retardation. published literature we are reliant on Recent advances in molecular genetic techniques have enabled us to understand attempting to draw conclusions from family and more about the molecular basis of several genetic syndromes associated with mental Search methodology twin studies, most of which are very old and retardation. In contrast, where there is no discrete cause, the interplay of genetic Electronic searching was done and the which report widely varying recurrence risks.[5] and environmental influences remains poorly understood. This article presents a relevant studies were identified by searching Recent studies of MMR have shown high rates critical review of literature on genetics of mental retardation.
    [Show full text]
  • Circle Applicable Codes
    IDENTIFYING INFORMATION (please print legibly) Individual’s Name: DOB: Last 4 Digits of Social Security #: CIRCLE APPLICABLE CODES ICD-10 ICD-10 ICD-9 DIAGNOSTIC ICD-9 DIAGNOSTIC PRIMARY ICD-9 CODES CODE CODE PRIMARY ICD-9 CODES CODE CODE Abetalipoproteinemia 272.5 E78.6 Hallervorden-Spatz Syndrome 333.0 G23.0 Acrocephalosyndactyly (Apert’s Syndrome) 755.55 Q87.0 Head Injury, unspecified – Age of onset: 959.01 S09.90XA Adrenaleukodystrophy 277.86 E71.529 Hemiplegia, unspecified 342.9 G81.90 Arginase Deficiency 270.6 E72.21 Holoprosencephaly 742.2 Q04.2 Agenesis of the Corpus Callosum 742.2 Q04.3 Homocystinuria 270.4 E72.11 Agenesis of Septum Pellucidum 742.2 Q04.3 Huntington’s Chorea 333.4 G10 Argyria/Pachygyria/Microgyria 742.2 Q04.3 Hurler’s Syndrome 277.5 E76.01 or 758.33 Aicardi Syndrome 333 G23.8 Hyperammonemia Syndrome 270.6 E72.4 Alcohol Embryo and Fetopathy 760.71 F84.5 I-Cell Disease 272.2 E77.0 Anencephaly 655.0 Q00.0 Idiopathic Torsion Dystonia 333.6 G24.1 Angelman Syndrome 759.89 Q93.5 Incontinentia Pigmenti 757.33 Q82.3 Asperger Syndrome 299.8 F84.5 Infantile Cerebral Palsy, unspecified 343.9 G80.9 Ataxia-Telangiectasia 334.8 G11.3 Intractable Seizure Disorder 345.1 G40.309 Autistic Disorder (Childhood Autism, Infantile 299.0 F84.0 Klinefelter’s Syndrome 758.7 Q98.4 Psychosis, Kanner’s Syndrome) Biotinidase Deficiency 277.6 D84.1 Krabbe Disease 333.0 E75.23 Canavan Disease 330.0 E75.29 Kugelberg-Welander Disease 335.11 G12.1 Carpenter Syndrome 759.89 Q87.0 Larsen’s Syndrome 755.8 Q74.8 Cerebral Palsy, unspecified 343.69 G80.9
    [Show full text]
  • 2018 Etiologies by Frequencies
    2018 Etiologies in Order of Frequency by Category Hereditary Syndromes and Disorders Count CHARGE Syndrome 958 Down syndrome (Trisomy 21 syndrome) 308 Usher I syndrome 252 Stickler syndrome 130 Dandy Walker syndrome 119 Cornelia de Lange 102 Goldenhar syndrome 98 Usher II syndrome 83 Wolf-Hirschhorn syndrome (Trisomy 4p) 68 Trisomy 13 (Trisomy 13-15, Patau syndrome) 60 Pierre-Robin syndrome 57 Moebius syndrome 55 Trisomy 18 (Edwards syndrome) 52 Norrie disease 38 Leber congenital amaurosis 35 Chromosome 18, Ring 18 31 Aicardi syndrome 29 Alstrom syndrome 27 Pfieffer syndrome 27 Treacher Collins syndrome 27 Waardenburg syndrome 27 Marshall syndrome 25 Refsum syndrome 21 Cri du chat syndrome (Chromosome 5p- synd) 16 Bardet-Biedl syndrome (Laurence Moon-Biedl) 15 Hurler syndrome (MPS I-H) 15 Crouzon syndrome (Craniofacial Dysotosis) 13 NF1 - Neurofibromatosis (von Recklinghausen dis) 13 Kniest Dysplasia 12 Turner syndrome 11 Usher III syndrome 10 Cockayne syndrome 9 Apert syndrome/Acrocephalosyndactyly, Type 1 8 Leigh Disease 8 Alport syndrome 6 Monosomy 10p 6 NF2 - Bilateral Acoustic Neurofibromatosis 6 Batten disease 5 Kearns-Sayre syndrome 5 Klippel-Feil sequence 5 Hereditary Syndromes and Disorders Count Prader-Willi 5 Sturge-Weber syndrome 5 Marfan syndrome 3 Hand-Schuller-Christian (Histiocytosis X) 2 Hunter Syndrome (MPS II) 2 Maroteaux-Lamy syndrome (MPS VI) 2 Morquio syndrome (MPS IV-B) 2 Optico-Cochleo-Dentate Degeneration 2 Smith-Lemli-Opitz (SLO) syndrome 2 Wildervanck syndrome 2 Herpes-Zoster (or Hunt) 1 Vogt-Koyanagi-Harada
    [Show full text]
  • Megalencephaly and Macrocephaly
    277 Megalencephaly and Macrocephaly KellenD.Winden,MD,PhD1 Christopher J. Yuskaitis, MD, PhD1 Annapurna Poduri, MD, MPH2 1 Department of Neurology, Boston Children’s Hospital, Boston, Address for correspondence Annapurna Poduri, Epilepsy Genetics Massachusetts Program, Division of Epilepsy and Clinical Electrophysiology, 2 Epilepsy Genetics Program, Division of Epilepsy and Clinical Department of Neurology, Fegan 9, Boston Children’s Hospital, 300 Electrophysiology, Department of Neurology, Boston Children’s Longwood Avenue, Boston, MA 02115 Hospital, Boston, Massachusetts (e-mail: [email protected]). Semin Neurol 2015;35:277–287. Abstract Megalencephaly is a developmental disorder characterized by brain overgrowth secondary to increased size and/or numbers of neurons and glia. These disorders can be divided into metabolic and developmental categories based on their molecular etiologies. Metabolic megalencephalies are mostly caused by genetic defects in cellular metabolism, whereas developmental megalencephalies have recently been shown to be caused by alterations in signaling pathways that regulate neuronal replication, growth, and migration. These disorders often lead to epilepsy, developmental disabilities, and Keywords behavioral problems; specific disorders have associations with overgrowth or abnor- ► megalencephaly malities in other tissues. The molecular underpinnings of many of these disorders are ► hemimegalencephaly now understood, providing insight into how dysregulation of critical pathways leads to ►
    [Show full text]
  • Saethre-Chotzen Syndrome
    Saethre-Chotzen syndrome Authors: Professor L. Clauser1 and Doctor M. Galié Creation Date: June 2002 Update: July 2004 Scientific Editor: Professor Raoul CM. Hennekam 1Department of craniomaxillofacial surgery, St. Anna Hospital and University, Corso Giovecca, 203, 44100 Ferrara, Italy. [email protected] Abstract Keywords Disease name and synonyms Excluded diseases Definition Prevalence Management including treatment Etiology Diagnostic methods Genetic counseling Antenatal diagnosis Unresolved questions References Abstract Saethre-Chotzen Syndrome (SCS) is an inherited craniosynostotic condition, with both premature fusion of cranial sutures (craniostenosis) and limb abnormalities. The most common clinical features, present in more than a third of patients, consist of coronal synostosis, brachycephaly, low frontal hairline, facial asymmetry, hypertelorism, broad halluces, and clinodactyly. The estimated birth incidence is 1/25,000 to 1/50,000 but because the phenotype can be very mild, the entity is likely to be underdiagnosed. SCS is inherited as an autosomal dominant trait with a high penetrance and variable expression. The TWIST gene located at chromosome 7p21-p22, is responsible for SCS and encodes a transcription factor regulating head mesenchyme cell development during cranial tube formation. Some patients with an overlapping SCS phenotype have mutations in the FGFR3 (fibroblast growth factor receptor 3) gene; especially the Pro250Arg mutation in FGFR3 (Muenke syndrome) can resemble SCS to a great extent. Significant intrafamilial
    [Show full text]